---
layout: default
title: Damoctocog Alfa Pegol
parent: 僅模型預測 (L5)
nav_order: 53
evidence_level: L5
indication_count: 0
---

# Damoctocog Alfa Pegol
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Damoctocog Alfa Pegol: Drug Repurposing Evaluation — Insufficient Data for Full Assessment

## One-Sentence Summary

Damoctocog Alfa Pegol (DB14700) is a PEGylated recombinant coagulation Factor VIII replacement therapy, primarily indicated for Hemophilia A. The TxGNN model has not generated any predicted new indications for this drug in the current analysis cycle, and the drug holds no marketing authorizations in Italy. Due to multiple critical data gaps — including absent MOA data, safety warnings, and TxGNN predictions — a complete repurposing evaluation cannot be conducted at this time.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Not retrieved from current data sources |
| Predicted New Indication | No TxGNN predictions generated |
| TxGNN Prediction Score | — |
| Evidence Level | L5 (no predictions or supporting studies available) |
| Italy Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this evidence pack. No TxGNN-predicted indications have been generated for Damoctocog Alfa Pegol in the current data cycle, making it impossible to assess mechanistic plausibility for any candidate new indication.

The original approved indication for this drug could not be confirmed from the evidence pack data sources. Based on publicly available knowledge, Damoctocog Alfa Pegol (brand name Jivi, by Bayer) is a B-domain–deleted recombinant human Factor VIII conjugated with a 60 kDa PEG moiety to extend its half-life, used in Hemophilia A management. However, since neither the indication text nor the mechanism of action has been formally ingested into this evidence pack, these details require verification before proceeding with any repurposing analysis.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for repurposing indications.

---

## Literature Evidence

Currently no related literature available for repurposing indications.

---

## Italy Market Information

Damoctocog Alfa Pegol currently holds no marketing authorizations in Italy. No product registration data is available from the current data sources.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
No TxGNN predictions are available for this drug, and two blocking data gaps — missing MOA data and absent safety/warnings data — prevent even a preliminary repurposing screen from being completed.

**To proceed, the following is needed:**

- **[Blocking]** Run TxGNN prediction pipeline for Damoctocog Alfa Pegol (DB14700) to generate candidate indications
- **[Blocking]** Retrieve TFDA/EMA package insert for safety warnings and contraindications (DG001)
- **[High]** Query DrugBank API for mechanism of action data (DG002)
- Confirm original approved indication text from a regulatory source (AIFA, EMA, or Bayer prescribing information)
- Once the above data gaps are resolved, re-run the full evidence pack generation (v5+) before proceeding to clinical plausibility review
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

